CD274 and hepatocellular carcinoma: An alternative treatment using a combination of atezolizumab (anti‐PD‐L1 antibody) and bevacizumab (anti‐VEGF antibody) was approved by the US Food and Drug Administration (FDA) for advanced HCC.